Abstract
In vitro assays developed for the evaluation of drug-like properties can accelerate the drug development process. The key assays are those for the evaluation of bioavailability, metabolic stability, drug-drug interaction potential, and toxicity. For bioavailability, the human colon carcinoma derived Caco-2 assay is the most widely used, allowing the evaluation of multiple pathways of intestinal absorption including paracellular uptake, transcellular uptake, and transporter-mediated uptake and efflux. For metabolic stability and drug-drug interactions, human liver microsomes, hepatocytes, and cDNA-expressed microsomes are commonly used, with human hepatocytes representing the most complete system, containing all metabolic enzymes and cofactors at physiological level and an intact plasma membrane to allow the modeling of intracellular drug concentrations. Primary human cells from target organs (e.g., human hepatocytes for human hepatotoxicity) should represent the best experimental system for the evaluation of human drug toxicity. These assays, when applied intelligently with their limitations, should greatly facilitate the selection of drug candidates with a high probability of clinical success.
Keywords: ADMET, enzymes, microsomes, hepatocytes, hepatotoxicity
Current Topics in Medicinal Chemistry
Title: In Vitro Approaches to Evaluate ADMET Drug Properties
Volume: 4 Issue: 7
Author(s): Albert P. Li
Affiliation:
Keywords: ADMET, enzymes, microsomes, hepatocytes, hepatotoxicity
Abstract: In vitro assays developed for the evaluation of drug-like properties can accelerate the drug development process. The key assays are those for the evaluation of bioavailability, metabolic stability, drug-drug interaction potential, and toxicity. For bioavailability, the human colon carcinoma derived Caco-2 assay is the most widely used, allowing the evaluation of multiple pathways of intestinal absorption including paracellular uptake, transcellular uptake, and transporter-mediated uptake and efflux. For metabolic stability and drug-drug interactions, human liver microsomes, hepatocytes, and cDNA-expressed microsomes are commonly used, with human hepatocytes representing the most complete system, containing all metabolic enzymes and cofactors at physiological level and an intact plasma membrane to allow the modeling of intracellular drug concentrations. Primary human cells from target organs (e.g., human hepatocytes for human hepatotoxicity) should represent the best experimental system for the evaluation of human drug toxicity. These assays, when applied intelligently with their limitations, should greatly facilitate the selection of drug candidates with a high probability of clinical success.
Export Options
About this article
Cite this article as:
Li P. Albert, In Vitro Approaches to Evaluate ADMET Drug Properties, Current Topics in Medicinal Chemistry 2004; 4 (7) . https://dx.doi.org/10.2174/1568026043451050
DOI https://dx.doi.org/10.2174/1568026043451050 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Facilitated/Pharmaco-invasive Approaches in STEMI
Current Cardiology Reviews Editorial from Guest Editor: Current Management of Sleep Apnea and Comorbidities
Current Respiratory Medicine Reviews Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology Latent Tuberculosis: Is There a Role for Thioridazine?
Recent Patents on Anti-Infective Drug Discovery Sodium Channel Inhibitor Drug Discovery Using Automated High Throughput Electrophysiology Platforms
Combinatorial Chemistry & High Throughput Screening Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery
Current Topics in Medicinal Chemistry Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Current Diabetes Reviews HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology